Advertisement
Home Tags Immunotherapy

Tag: Immunotherapy

A single checkpoint inhibitor can be used to successfully treat two simultaneous types of primary cancer in a patient with Lynch syndrome

Single Agent Treats Two Cancers With Same Genetic Cause

0
Pembrolizumab treated colon cancer, intrahepatic cholangiocarcinoma in patient with Lynch syndrome
Checkpoint blockade immunotherapy is associated with significant increases in overall survival in a real-world population of patients undergoing treatment for melanoma brain metastases

Novel Immunotherapy May Up Survival in Melanoma Brain Mets

0
Findings in patients receiving checkpoint blockade immunotherapy for melanoma brain metastases
A new immunotherapy appears to be well tolerated and possibly of benefit in patients with amyotrophic lateral sclerosis

Immunotherapy Promising for Slowing Progression of ALS

0
Positive results seen for autologous infusions of expanded regulatory T lymphocytes in three patients
A highly personalized therapy targeting multiple tumor antigens shows promise for metastatic breast cancer

Personalized Therapy Promising in Metastatic Breast Cancer

0
Adaptive transfer of mutant-protein-specific tumor-infiltrating lymphocytes leads to disease regression
For patients with advanced cancers

Immune Checkpoint Inhibitor Efficacy Varies by Sex

0
Magnitude of benefit of immune checkpoint inhibitors sex-dependent for patients with advanced cancers
Patients receiving immunotherapy with antiprogrammed cell death protein-1 and antiprogrammed cell death ligand-1 monoclonal antibodies may develop uveal effusion

Uveal Effusion Reported After Initiation of Anti-PD-1, -PD-L1

0
Case series IDs three patients who developed uveal effusion within one to two months of initiating tx
Gemcitabine and cisplatin plus ipilimumab is associated with a 69 percent objective response rate and 61 percent one-year overall survival for patients with metastatic urothelial cancer

Chemo, Immunotherapy Feasible in Metastatic Bladder Cancer

0
One-year overall survival of 61 percent for gemcitabine and cisplatin plus ipilimumab
Immunotherapy with peptide hydrolysates from Lolium perenne reduces seasonal allergy symptoms and is generally well tolerated

Grass Peptide Immunotherapy Cuts Seasonal Allergy Symptoms

0
Subcutaneous injections administered over three-week period before grass pollen season
A 250-μg peanut patch produces a significant treatment response in peanut-allergic patients treated for a year

Peanut Patch Found Safe, Effective for Treating Allergies

0
250-μg patch produces significant treatment response compared with placebo after 12 months
Response to immunosuppressive therapy predicts overall survival in aplastic anemia

Immunosuppressant Response Predicts Aplastic Anemia Survival

0
Overall survival superior in therapy responders; shorter relapse-free survival with partial response